International guidelines (ASCO/NCCN, ESO–ESMO BCY5) consistently advocate for ovarian suppression, typically utilizing a GnRH agonist, tamoxifen, or an aromatase inhibitor, for premenopausal women diagnosed with hormone receptor-positive breast cancer at moderate to high risk of recurrence [20]. Here, NR4A1 is linked to breast carcinoma.